AMPK Pathway Research
AICAR is one of the standard pharmacological AMPK activators used as a positive control in pathway work.

AMPK Activation Studies
Get an email when AICAR is back
Leave your email and we will send one note the moment it is back in stock.
One email when it restocks, plus occasional Eon updates. Unsubscribe anytime.
Free Shipping on orders over $200
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
Researchers also added
Research use only.
The Eon standard
Your results are only as good as your compound.
Every lot of AICAR is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement.
Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
AICAR is an adenosine analog widely used as a pharmacological AMPK activator in metabolic research. Inside the cell it is phosphorylated to ZMP, an AMP mimetic that allosterically activates AMP-activated protein kinase. It is one of the standard reference tools for AMPK-pathway work in culture and in rodent models. For laboratory research use only.
Adenosine analog studied as an AMPK pathway activator
The numbers that define AICAR and how it is being studied. For laboratory research use only.
AMP-activated protein kinase
Lyophilized powder
AMP mimetic formed intracellularly
The pathways AICAR acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
AICAR is taken up by adenosine transporters and phosphorylated to ZMP. ZMP mimics AMP and allosterically activates AMPK without changing cellular AMP levels, which is what makes AICAR a standard pharmacological tool.
AMPK activation is measured by phosphorylation of downstream substrates including acetyl-CoA carboxylase. Glucose-uptake and fatty-acid-oxidation endpoints follow in the characterised literature.
Downstream PGC-1α signalling and mitochondrial biogenesis endpoints are characterised in skeletal muscle models.
The main areas AICAR is being studied for - and the study-reported figures behind them.
AICAR is one of the standard pharmacological AMPK activators used as a positive control in pathway work.
Glucose-uptake endpoints in skeletal muscle culture are widely characterised.
PGC-1α signalling and biogenesis endpoints are measured downstream of AMPK activation.
Frequently used as a characterised reference activator in assay development.
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
| Chemical Name | AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) |
| Class | Adenosine analog / AMPK activator |
| Content | 50 mg per vial |
| Active Metabolite | ZMP (AMP mimetic) |
| Pathway Target | AMP-activated protein kinase (AMPK) |
| Form | Lyophilized powder |
| Purity | ≥99% by HPLC |
| Solubility | Water, DMSO |
| Storage | -20°C, protected from light |
| Classification | Research use only |
It is converted intracellularly to ZMP, which mimics AMP and activates AMPK allosterically without altering the cell's actual AMP levels. That lets a protocol activate the pathway pharmacologically.
No. It is a small-molecule adenosine analog, not a peptide. It is included here as a metabolic-research reference compound.
The molecular weight will be published here from the lot's Certificate of Analysis rather than quoted from a secondary source.
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.